What is Myozyme?
Myozyme is the brand name for alglucosidase alfa, an enzyme replacement therapy used to treat late-onset Pompe disease in patients who have signs of muscle involvement. [1]
What condition does Myozyme treat (Pompe disease)?
Pompe disease is a genetic disorder caused by insufficient activity of an enzyme needed to break down glycogen inside cells. Myozyme provides a lab-produced version of that missing enzyme to help reduce glycogen buildup, particularly in muscle. [1]
How is Myozyme given?
Myozyme is given by intravenous (IV) infusion. [1]
Who might be eligible to receive Myozyme?
Myozyme is used for late-onset Pompe disease with muscle involvement, as described in the prescribing information. [1]
What are common side effects people ask about?
The prescribing information for Myozyme lists side effects and infusion-related reactions associated with enzyme replacement therapies. To identify the most relevant side effects for a specific patient, it’s important to review the full prescribing information and discuss it with the treating clinician. [1]
How does Myozyme compare with other Pompe therapies?
For late-onset Pompe disease, the main therapy class is enzyme replacement. Whether Myozyme is the right option versus alternatives depends on indication details, patient history, infusion tolerance, and clinician judgment. (Compare products by their approved indications and dosing/infusion guidance in their respective prescribing information.) [1]
Where to find dosing and safety details
The most reliable source for dosing schedules, contraindications, warnings (including infusion reactions), and full adverse-event information is the official prescribing information. [1]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/